1.Joerger M, Schellens JH, Beijnen JH. Therapeutic drug monitoring of non-anticancer drugs in cancer patients. Methods Find Exp Clin Pharmacol 2004; 26:531-545.
2.Eilers R. Therapeutic drug monitoring for the treatment of psychiatric disorders. Clinical use and cost effectiveness. Clin Pharmacokinet 1995; 29:442-450.
3.Reith DM, Andrews J, McLaughlin D. Valproic acid has temporal variability in urinary clearance of metabolites. Chronobiol Int 2001; 18:123-129.
4.Evans WE, Schentag JJ, Jasko WJ. Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring. 3rd ed. Lippincott Williams & Wilkins; 1992.
5.DeVane CL. Pharmacokinetics, drug interactions, and tolerability of valproate. Psychopharmacol Bull 2003; 37:25-42.
6.Lagace DC, O'Brien WT, Gurvich N, Nachtigal MW, Klein PS. Valproic acid: How it works. Or not. Clin Neurosci Res 2004; 4:215-225.
7.Fattore C, Messina S, Battino D, Croci D, Mamoli D, Perucca E. The influence of old age and enzyme inducing comedication on the pharmacokinetics of valproic acid at steady-state: A case-matched evaluation based on therapeutic drug monitoring data. Epilepsy Res 2006; 70:153-160.
8.Jiang Z, Zhang J, Liao HM, Tang JW, Peng QL. Influence of age, body weight and dose on sodium valproate plasma concentrations in children with epilepsy. Zhongguo Dang Dai Er Ke Za Zhi 2008; 10:325-328.
9.Perucca E, Aldenkamp A, Tallis R, Kramer G. Role of valproate across the ages. Treatment of epilepsy in the elderly. Acta Neurol Scand Suppl 2006; 184:28-37.
10.Sharma S, Joshi S, Mukherji S, Bala K, Tripathi CB.Therapeutic Drug Monitoring: Appropriateness and Clinical Utility in Neuropsychiatry Practice. Am J Ther 2008 (In Press).
11.Gidal BE, Pitterle ME, Spencer NW, Maly MM. Relationship between valproic acid dosage, plasma concentration and clearance in adult monotherapy patients with epilepsy. J Clin Pharm Ther 1995; 20:215-519.